At a similar stage to Cscreen+ is bTBscreen+, another rapid point of use test based on lateral flow technology. This test is being developed primarily for use in the battle against bovine tuberculosis (bTB) a devastating disease affecting many animals at huge cost and disruption to farming communities, global economies and takes a huge toll on many indigenous animal populations. This low cost, rapid & highly accurate diagnostic technology is the result of many years of ground-breaking collaborative research at Aberystwyth University and facilitates a completely new approach to the monitoring and testing of bTB. The associated data platform will aid research, monitoring and protection of the food chain.
It is estimated that monthly screening tests for bTB in cattle herds in the UK alone using this rapid point of use test could be in the region of 1million within 6 months of commercialisation. bTBscreen+ has a global addressable market of 1.5 billion head of cattle x 6 tests annually and work continues to validate the use of the same ground-breaking outcomes from the research to develop similar tests to diagnose and inform treatment for TB in all animals and people .
iOmics develops diagnostic technologies addressing major issues in human and animal health. The technology is based on research from Aberystwyth University and the business is managed by an experienced commercial team. The company will license Intellectual Property from this research to commercial organisations and generate revenue from licence fees and royalties. The chain of rights to IP exists and vests in the company.
Additional research projects in hand are developing solutions these areas: sleep apnea, human TB, respiratory diseases, urogenital diseases, prostate cancer.
Cscreen+ and bTBscreen+ are intended for international commercialisation. iOmics will charge annual fees for licences and a royalty per test.
Growth potential is exceptional. These initial two projects meet immediate world-wide challenges. In addition to current projects, iOmics intends to develop several new projects each year based on its IP building a pipeline of new ground breaking commercial opportunities that will positively impact human and animal health and agri-food safety across the world.
Investment of £500,000 is sought to bring bTBscreen+ to market within twelve months post- investment and likewise CSecreen+. Investment can be into a ringfenced project or into the business which would include an interest in all current and future projects. Funds will create 7 jobs immediately and a further 12 Q3 ‘22 onwards. This is an early stage, pre-revenue, IP based business opportunity and interested parties should take appropriate legal advice.
The founders and partners
Aberystwyth University.
Keir Lewis, Professor of Respiratory Medicine, Swansea University & Hywel Dda UHB (NHS).
Luis Mur, Professor at Institute Biological Environmental and Rural Sciences, Aberystwyth
Dr David Rooke, ProTEM Services. Translational science and technology.
Ian Bond, Bond Digital Holdings. Data management.
Dr David West, Clarity Bio. Lateral flow technology,
The management team
Ian Bond CEO. Founder Bond Digital Health.
Dr David Rooke. Founder ProTEM Services Ltd.
Further Information
For further information on the business and projects
contact Ian Bond ian.bond@iomics.co.uk (+44)7731087823